Valion Bio (VBIO) Income from Continuing Operations (2021 - 2026)
Valion Bio (VBIO) posted quarterly Income from Continuing Operations of 73000.0 for Q4 2025, up 104.83% year-over-year from 35638.54 in Q4 2024, and up 102.94% quarter-over-quarter from 2479000.0 in Q3 2025.
Valion Bio (VBIO) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Valion Bio's Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 73000.0 for Q4 2025.
- In Q4 2025, Income from Continuing Operations rose 104.83% year-over-year to 73000.0; the TTM figure through Dec 2025 stood at 5846000.0 (down 0.81% YoY), while the FY2025 annual figure was 301000.0, up 94.86% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 73000.0, up from 2479000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 73000.0 in Q4 2025, with the low at 3068000.0 in Q2 2022.
- The 5-year median for Income from Continuing Operations is 1872500.0 (2023), against an average of 1841000.0.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations sank 140.06% in 2022, then surged 104.83% in 2025.
- Valion Bio's Income from Continuing Operations stood at 2292000.0 in 2021, then declined by 0.65% to 2307000.0 in 2022, then grew by 0.48% to 2296000.0 in 2023, then surged by 34.23% to 1510000.0 in 2024, then jumped by 104.83% to 73000.0 in 2025.
- Business Quant data shows VBIO's Income from Continuing Operations at 73000.0 in Q4 2025, 2479000.0 in Q3 2025, and 1934000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | Valion Bio | 420,133.64 | -1.78 Mn | -45,000.00 | -45,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.62 Mn |
| Dec 31, 2025 | 73,000.00 |
| Sep 30, 2025 | -2.48 Mn |
| Jun 30, 2025 | -1.93 Mn |
| Mar 31, 2025 | -1.51 Mn |
| Dec 31, 2024 | -1.51 Mn |
| Sep 30, 2024 | -1.43 Mn |
| Jun 30, 2024 | -1.33 Mn |
| Mar 31, 2024 | -1.53 Mn |
| Dec 31, 2023 | -2.30 Mn |
| Sep 30, 2023 | -1.81 Mn |
| Jun 30, 2023 | -2.18 Mn |
| Mar 31, 2023 | -2.17 Mn |
| Dec 31, 2022 | -2.31 Mn |
| Sep 30, 2022 | -2.63 Mn |
| Jun 30, 2022 | -3.07 Mn |
| Mar 31, 2022 | -2.56 Mn |
| Dec 31, 2021 | -2.29 Mn |
| Sep 30, 2021 | -1.23 Mn |
| Jun 30, 2021 | -1.28 Mn |